ライフサイエンスコーパス: severe obesity

1 cterized by a high accumulation of body fat (severe obesity).

2 s currently the most effective treatment for severe obesity.

3 from mice or humans leads to hyperphagia and severe obesity.

4 fter surgical and conventional treatments of severe obesity.

5 ient to achieve weight loss in patients with severe obesity.

6 adipose tissues of patients with T2D and/or severe obesity.

7 eased risk, particularly for long-lasting or severe obesity.

8 iatric surgery is an effective treatment for severe obesity.

9 r acute ischemic stroke, less is known about severe obesity.

10 s in leptin and the LepR have low BP despite severe obesity.

11 es in bone and mineral metabolism related to severe obesity.

12 tant from insulin-sensitive individuals with severe obesity.

13 skeletal muscle insulin sensitivity, despite severe obesity.

14 markedly enhanced food intake, resulting in severe obesity.

15 y to prevent cardiovascular complications in severe obesity.

16 y, except for those with at least moderately severe obesity.

17 nical trials have evaluated the treatment of severe obesity.

18 ntly associated with incident obesity and/or severe obesity.

19 Similar results were found for severe obesity.

20 had mild developmental delay in addition to severe obesity.

21 ree patients the deletion co-segregated with severe obesity.

22 s needed on the prognostic influence of more severe obesity.

23 ricular function in patients with clinically severe obesity.

24 is mediated some of the protective effect of severe obesity.

25 tly increase the risk of obesity, especially severe obesity.

26 in obese individuals, especially those with severe obesity.

27 in its gene (NTRK2) lead to hyperphagia and severe obesity.

28 ed with depression mainly among persons with severe obesity.

29 omized 7B2 nulls also developed unexpectedly severe obesity.

30 function mutations has been associated with severe obesity.

31 number of genes that when mutated result in severe obesity.

32 as its absence in rodents and humans causes severe obesity.

33 eptin, were used to study the role of p55 in severe obesity.

34 racial differences in obesity, specifically severe obesity.

35 is a safe and effective treatment option for severe obesity.

36 n or resistance to the protein leptin causes severe obesity.

37 ty, and 4.3 (95% CI, 2.8-6.5) for those with severe obesity.

38 y, and 9.4 (95% CI, 6.6-13.5) for those with severe obesity.

39 1 in 3 youths overall and 1 in 2 youths with severe obesity.

40 portant weight loss tool in individuals with severe obesity.

41 besity-related cancer in NAFLD patients with severe obesity.

42 more likely in adolescents and in those with severe obesity.

43 ve treatments for individuals diagnosed with severe obesity.

44 Roux-en-Y gastric bypass in the treatment of severe obesity.

45 with previous myocardial infarction (MI) and severe obesity.

46 timate the prevalence of obesity, especially severe obesity.

47 es were doubled in offspring of mothers with severe obesity.

48 tric surgery is an underutilized therapy for severe obesity.

49 d is often the only option for subjects with severe obesity.

50 d Pomc mutations may lead to hyperphagia and severe obesity.

51 r the treatment of obesity, in patients with severe obesity.

52 (95% UI, 2.43 to 3.65) for 19-year-olds with severe obesity.

53 fibrillation among persons being treated for severe obesity.

54 ent of anticoagulant dosing in patients with severe obesity.

55 is (LF) in European cohorts of patients with severe obesity.

56 ement and reduce mortality for patients with severe obesity.

57 these important outcomes in adolescents with severe obesity.

58 rove insulin sensitivity in individuals with severe obesity.

59 result in a metabolic disorder that includes severe obesity(1), and defects in thermogenesis(2) and l

60 ing conditions (vs without) (5.0 [3.9-6.3]), severe obesity (4.4 [3.4-5.7]), chronic kidney disease (

61 ecovered), 490 children and adolescents with severe obesity, 445 healthy-lean adult individuals and 1

62 ts aged 12 to 17 years (mode, 15 years) with severe obesity (62% female).

63 variants influencing BMI also contribute to severe obesity, a condition at the extreme of the phenot

64 Among patients with severe obesity, a lifestyle intervention involving diet

65 OB mothers developed severe obesity accompanied by higher maternal and fetal

66 owing inequality in the risk for obesity and severe obesity across GPS tenths.

67 in weight and a 25-fold gradient in risk of severe obesity across polygenic score deciles.

68 Severe obesity affects 4% to 6% of US youth and is incre

69 Severe obesity afflicts between 4% and 6% of all youth i

70 and sex-specific BMI >=95th percentile), and severe obesity (age- and sex-specific BMI >=120% of the

71 an independent sample of 1,062 patients with severe obesity alone, the smaller 16p11.2 deletion was f

72 subjects were characterized by hyperphagia, severe obesity, alterations in immune function, and dela

73 udy suggested that the greater prevalence of severe obesity among African-American women explained al

74 The higher prevalence of severe obesity among black women may play an important r

75 The prevalence of severe obesity among children and young adults has incre

76 se methods were applied to a large data set, severe obesity and BIV prevalence ranged from 7.2% to 8.

77 Ms J is a 52-year-old woman with severe obesity and depression, anxiety, and osteoarthrit

78 exact role of surgery in patients with less severe obesity and diabetes are considered a priority.

79 in or its receptor have been associated with severe obesity and diabetes, such mutations do not appea

80 sessed metabolic alterations associated with severe obesity and distinct bariatric procedures.

81 Further validation in cohorts with severe obesity and engineering the variants in model org

82 ing performed on adolescents with clinically severe obesity and experience suggests that it is effect

83 have elevated plasma proinsulin and develop severe obesity and hyperglycemia.

84 because disruption of the POMC gene leads to severe obesity and hyperphagia.

85 on in POMC in a child of Turkish origin with severe obesity and hypoadrenalism.

86 E1m-/+ mice had more severe obesity and insulin resistance and lower metaboli

87 leus (Arc)POMC-deficient mice, which develop severe obesity and insulin resistance, unexpectedly exhi

88 2 diabetes in cells and in a mouse model of severe obesity and insulin resistance.

89 othalamus and paraventricular nucleus showed severe obesity and insulin resistance.

90 tion, a macrophage phenotype associated with severe obesity and insulin resistance.

91 B1 and humans with variants of SH2B1 display severe obesity and insulin resistance.

92 is occurring in conjunction with the rise of severe obesity and is probably mediated in part by metab

93 ective and increasingly common treatment for severe obesity and its many comorbidities.

94 Severe obesity and its related diseases, such as type 2

95 Bariatric surgery effectively treats severe obesity and metabolic diseases.

96 ither leptin or its receptor (LepR) leads to severe obesity and metabolic disorders.

97 c bypass (RYGB) is an effective treatment of severe obesity and one of the fastest growing surgical p

98 analyses evaluated the relationship between severe obesity and short-term outcomes and long-term mor

99 he management of adolescents with clinically severe obesity and should be performed by specialists de

100 ency or resistance, respectively, results in severe obesity and the development of a syndrome resembl

101 atory cases, including those associated with severe obesity and vocal cord dysfunction (VCD).

102 ader-Willi-like syndrome features (including severe obesity) and 4 other rare variants (p.T46R, p.E62

103 rweight, mild obesity, moderate obesity, and severe obesity) and fibrosis stage (F0-F3).

104 MC) results in a syndrome of hypoadrenalism, severe obesity, and altered skin and hair pigmentation.

105 acious and enduring treatment for clinically severe obesity, and as a result, the number of bariatric

106 All patients with severe obesity-and especially those with type 2 diabetes

107 rrent US MBS utilization rates in those with severe obesity; and (2) utilization rates and 30-day pos

108 obesity (aPR, 2.16; 95% CI, 2.14-2.19), and severe obesity (aPR, 2.53; 95% CI, 2.50-2.57).

109 general population, obesity and, especially, severe obesity are consistently and strongly related wit

110 GRM7, that confer about three-fold risk for severe obesity, are expressed in the brain and adipose t

111 Advice 2: EBTs can be used in patients with severe obesity as a bridge to traditional bariatric surg

112 ht children and adolescents progress towards severe obesity as adults.

113 chromosomal loci existed that were linked to severe obesity, as well as to utilize the increased heri

114 nding--62+/-52 months ago for the control of severe obesity associated with PTC.

115 firm link between SIM1 loss of function and severe obesity associated with, or independent of, Prade

116 went Roux-en-Y gastric bypass for clinically severe obesity at a paediatric academic medical centre i

117 ted deletion of Mrap2, both of which develop severe obesity at a young age.

118 his large, multisite cohort of patients with severe obesity, bariatric surgery was associated with a

119 a staged approach for surgical treatment of severe obesity between January 2002 and February 2004.

120 kg/m2) increased markedly, and prevalence of severe obesity (BMI > or = 40.0 kg/m2) doubled in all ra

121 sk prediction overall, even among those with severe obesity (BMI >/=35 kg/m(2); improvement in C stat

122 were used for obesity (BMI >= 30 kg/m2) and severe obesity (BMI >= 35 kg/m2).

123 Severe obesity (BMI >=40 kg/m(2)) was associated with an

124 19 participants with severe obesity (BMI 38.3 +/- 5.3 kg/m(2)) were treated w

125 cular disease, cerebrovascular accident, and severe obesity (body mass index > or = 35 kg/m2).

126 esity (body mass index > or =30 kg/m(2)) and severe obesity (body mass index > or =35 kg/m(2)) was ev

127 Severe obesity (body mass index >/=35 [calculated as wei

128 ditions, except that EA had a higher rate of severe obesity (body mass index >35).

129 ric surgery is recommended for patients with severe obesity (body mass index >=40) and type 2 diabete

130 esence of significant co-morbidities such as severe obesity (body mass index 35), diabetes, or cardio

131 Severe obesity (body mass index [BMI] >/=35) is associat

132 dren and adolescents aged 8 to 18 years with severe obesity (body mass index [BMI] z score, >/=3.0 or

133 mary THA for osteoarthritis and who also had severe obesity (body mass index [calculated as weight in

134 Severe obesity (body mass index of >or=35: RR = 1.29, 95

135 Class 3 (severe) obesity (body mass index > or =40) was associate

136 r for children with overweight, obesity, and severe obesity but lower for children with underweight c

137 idered for the treatment of adolescents with severe obesity, but few prospective adolescent-specific

138 fective weight loss option for Veterans with severe obesity, but fewer than 0.1% of Veterans with sev

139 urgery improves survival among patients with severe obesity, but research among veterans has shown no

140 GBS is increasingly used to treat severe obesity, but there are limited outcome data.

141 Nearly 1 in 4 adults is projected to have severe obesity by 2030 (24.2%; 95% CI, 22.9 to 25.5), an

142 ver a sham procedure.(The Lowering Weight in Severe Obesity by Embolization of the Gastric Artery Tri

143 c mouse model of early-onset hyperphagia and severe obesity by selectively blocking the expression of

144 Severe obesity can result in proteinuria and progressive

145 ry care may improve access to evidence-based severe obesity care within VA.

146 n with underweight, overweight, obesity, and severe obesity compared with children with healthy weigh

147 A total of 1156 patients with severe obesity comprised three groups: 418 patients who

148 he impact of mild (D-BMI, 30-35 kg/m) versus severe obesity (D-BMI, >/=35 kg/m) on pancreas allograft

149 long-term outcomes are few, many youth with severe obesity do not qualify for surgery, and access is

150 d Koletsky (fa(k)/fa(k)) rats, which develop severe obesity due to the genetic absence of leptin rece

151 -) and heterozygotic (neil1+/-) mice develop severe obesity, dyslipidemia, and fatty liver disease an

152 eady at mildly elevated body weight, whereas severe obesity entailed an almost 5-fold increase in ris

153 ctomy as a definitive therapeutic option for severe obesity, even in high-risk, high-BMI patients.

154 mutations in MC4R are a significant cause of severe obesity, extending this finding to North American

155 th obesity alone, screening of children with severe obesity for GNAS deficiency may allow early diagn

156 onding absolute changes in the prevalence of severe obesity for men and women, respectively, were 8.5

157 The severe obesity found in these congenitally leptin-defici

158 in 262 Caucasian subjects with a history of severe obesity from childhood.

159 y and other risk factors, male patients with severe obesity-grade 3 obesity [adjusted odds ratio (AOR

160 Patients with severe obesity (> or =35) did not have increased total m

161 5 to <30), moderate obesity (30 to <35), and severe obesity (>=35).

162 25.0-29.9), (3) obesity (30.0-34.9), and (4) severe obesity (>=35.0) using the World Health Organizat

163 weight (25.0-29.9), obesity (30.0-34.9), and severe obesity (>=35.0).

164 y (30.0-34.9 kg/m(2)), and class II and III (severe) obesity (>/=35.0 kg/m(2)).

165 besity: 100% to <120% of 95th percentile; or severe obesity: >=120% of 95th percentile), age, sex, ra

166 Male and female patients with severe obesity had a 2.5- to 4-fold higher risk of devel

167 Boys with severe obesity had the greatest risk for earlier gonadar

168 t a significant fraction of individuals with severe obesity has active BAT.

169 Although severe obesity has received much attention in the clinic

170 -based treatment interventions in youth with severe obesity have demonstrated modest improvement in b

171 Adolescents with severe obesity have musculoskeletal pain that limits the

172 ptin deficiency, which includes hyperphagia, severe obesity, hypogonadism, and impaired immunity, has

173 Adults with severe obesity (ie, body mass index of 35 or greater) un

174 ost-effective treatment for adolescents with severe obesity if assessed over a time horizon of 5 year

175 Adjustment for severe obesity in a logistic regression model reduced th

176 therapy use predict incident obesity and/or severe obesity in a multiracial cohort of women transiti

177 of the orexin neurons develop hypophagia and severe obesity in addition to the narcolepsy phenotype.

178 Severe obesity in adolescence is associated with reduced

179 eceptor agonist therapy for the treatment of severe obesity in adolescents.

180 ED displayed a markedly higher prevalence of severe obesity in adulthood (body mass index >/=40) than

181 over time to determine whether they develop severe obesity in adulthood, thus limiting effective int

182 y associated with increased risk of incident severe obesity in adulthood, with variations by sex and

183 of-function mutations in either gene causing severe obesity in both mice and humans.

184 Severe obesity in childhood is a major health problem wi

185 associated with adult obesity and a few with severe obesity in childhood; however, less progress has

186 r and recommend a standardized definition of severe obesity in children and adolescents; (2) raise aw

187 Severe obesity in children and young adults was associat

188 genetic variation in TBC1D1 confers risk for severe obesity in females.

189 percentage of the genetic predisposition to severe obesity in females.

190 encoding NTRK2 gene have been found to cause severe obesity in humans and mice.

191 ignaling to energy balance dysregulation and severe obesity in humans and rodents.

192 C1D1 R125W missense variant confers risk for severe obesity in humans.

193 of the MC4R promoter may also be a cause of severe obesity in humans.

194 MC4R promoter is not a significant cause of severe obesity in humans.

195 Its disruption causes severe obesity in mice and humans.

196 unction of MC4R or MC3R were associated with severe obesity in North American adults.

197 te hormone leptin and the demonstration that severe obesity in ob/ob and db/db mice results from muta

198 in 4 receptor in the PVN, is responsible for severe obesity in our subject.

199 determine whether MC4R has a role in causing severe obesity in Pima Indians, we sequenced the coding

200 e of its natural variants, Ob-Ra, results in severe obesity in rodents.

201 or of energy homeostasis and its loss causes severe obesity in rodents.

202 diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or

203 that MC3R mutations are not associated with severe obesity in this population.

204 confirmed in an independent linkage study of severe obesity in Utah pedigrees.

205 comparing LSG and LRYGB in the treatment of severe obesity in which 240 patients aged 18 to 60 years

206 ts were significantly more likely to develop severe obesity in young adulthood than normal-weight or

207 cohort of 327 children and adolescents with severe obesity, in whom liver fibrosis was evaluated by

208 s limiting effective interventions to reduce severe obesity incidence and its potentially life-threat

209 -age growth chart or BMI >/=30.0) on risk of severe obesity incidence in adulthood (aged >/=20 years;

210 Of the 206 adolescents with severe obesity included in the study, 156 were female (7

211 roviders who delivered care to veterans with severe obesity, including bariatric surgeons, primary ca

212 From 2015-2018 the US prevalence of youth severe obesity increased in Hispanics and non-Hispanic b

213 The odds of incident severe obesity increased with surgical menopause (odds r

214 rotein SH2B1 (SH2-B, PSM) is associated with severe obesity, insulin resistance, and neurobehavioral

215 revalent among children and adolescents with severe obesity, irrespective of ethnic group.

216 ishing weight loss is the determination that severe obesity is a disease associated with multiple adv

217 Severe obesity is a rapidly growing global health threat

218 Severe obesity is associated with a risk of lower extrem

219 Severe obesity is associated with increased poststroke m

220 Severe obesity is associated with mobility limitations a

221 Severe obesity is associated with multiple comorbidities

222 e that bariatric surgery in adolescents with severe obesity is associated with significant improvemen

223 urgery for the treatment of adolescents with severe obesity is becoming more common, but data on cost

224 Severe obesity is characterized by specific additional c

225 Severe obesity is common before and after liver transpla

226 Treatment of severe obesity is difficult; in the past, lifestyle meas

227 Severe obesity is frequently associated with significant

228 r of patients with myocardial infarction and severe obesity is increasing and there is a lack of evid

229 The prevalence of severe obesity is increasing markedly, as is prevalence

230 Severe obesity is increasingly common in the adolescent

231 We predict that, nationally, severe obesity is likely to become the most common BMI c

232 The prevalence of severe obesity is rising in the United States.

233 Severe obesity is the fastest growing subcategory of obe

234 anial hypertension), a known complication of severe obesity, is associated with severe headaches, pul

235 ntrols identified 4 new loci associated with severe obesity (LEPR, PRKCH, PACS1 and RMST).

236 ery is the most cost-effective treatment for severe obesity, less than 1% of severely obese patients

237 On average, individuals with severe obesity lived 10 fewer years without glucose impa

238 a, with low level lead intoxication, or with severe obesity/metabolic syndrome.

239 port a 19-year-old male with hyperphagia and severe obesity, mild learning difficulties and hypogonad

240 ormalizing body fat content in patients with severe obesity, more aggressive treatments have been stu

241 re well known to cause leptin deficiency and severe obesity, no common loci regulating circulating le

242 However, despite severe obesity, ob/ob-aP2-mal1(-/-) mice remained euglyc

243 gain a better understanding of the impact of severe obesity on trauma outcomes.

244 impact of donors with body mass index >=40 (severe obesity) on heart transplant outcomes.

245 dds ratio [OR], 2.47; 95% CI, 1.36 to 4.51), severe obesity (OR, 4.04; 95% CI, 1.46 to 11.19), and ed

246 associated with the risk of type 2 diabetes, severe obesity, or marked hyperinsulinemia, but that the

247 Our data highlight the leading role of severe obesity over correlated risk factors, providing a

248 ion candidates also exhibited an increase in severe obesity over time, from 3.5% to 6.8%, with a lowe

249 p = 3 x 10(-14)), 62.3% increase in risk for severe obesity (p = 1 x 10(-6)), and median 5.29 years e

250 EGR1 locus was significantly associated with severe obesity (P = 6.6 x 10(-7)).

251 of the DOCK5 VNTRs with childhood and adult severe obesity (P(empirical)= 8.9 x 10(-8) and P= 3.1 x

252 a TBC1D1 variant associate this protein to a severe obesity phenotype.

253 In this series, adolescents with severe obesity presented with abundant comorbid conditio

254 oss-sectional data (N = 19,225) generated US severe obesity prevalence estimates.

255 surgery is the most effective treatment for severe obesity, producing marked sustained weight loss w

256 years, cumulative incidences of obesity and severe obesity reached 21.8% and 12.3%, respectively.

257 20%; adjustment for both waist:hip ratio and severe obesity reduced the odds ratio by 27%.

258 ructural variants) responsible for childhood severe obesity remains elusive.

259 ot associated with an increased YLL and only severe obesity resulted in YLL.

260 rs (RR, 2.08; 95% CI, 1.53-2.83); and higher severe obesity risk at 5 years (RR, 1.21; 95% CI, 0.95-1

261 These data suggest that GBP surgery for severe obesity should be provided earlier to patients to

262 d be considered for patients with clinically severe obesity, since currently it appears to offer the

263 gan Sharing database and stratified by donor severe obesity status (body mass index >=40).

264 NHANES data to assess trends in obesity and severe obesity stratified by race and Hispanic origin am

265 alterations in each of these axes result in severe obesity, such cases remain rare.

266 ic surgery is the most effective therapy for severe obesity that can reduce body weight and obesity-a

267 ostatic control system is highlighted by the severe obesity that results from dysfunction of any of s

268 For children with severe obesity, the chance they will no longer be obese

269 isceral adipose tissue; and 2) patients with severe obesity, the latter group having distinct additio

270 Among participants with severe obesity, there was substantial weight loss 3 year

271 besity, but fewer than 0.1% of Veterans with severe obesity undergo it.

272 Adults with severe obesity undergoing bariatric surgery were recruit

273 Among a cohort of participants with severe obesity undergoing bariatric surgery, a large per

274 study of adolescents (aged 13-18 years) with severe obesity undergoing Roux-en-Y gastric bypass at th

275 INTERPRETATION: Adolescents with severe obesity undergoing Roux-en-Y gastric bypass had s

276 eight, class 1 obesity, class 2 obesity, and severe obesity) using Kaplan-Meier methods.

277 spanic White) (2.7%, 95% CI 1.5%-4.8%), with severe obesity (versus under/normal weight) (3.9%, 95% C

278 Severe obesity was associated with an approximately twof

279 Severe obesity was associated with both race and stage a

280 ared with milder forms of obesity, extremely severe obesity was associated with higher odds of metabo

281 Severe obesity was defined as a body-mass index (BMI, th

282 le with a complex developmental syndrome and severe obesity was heterozygous for a de novo missense m

283 Donor severe obesity was not associated with adverse post-tran

284 verely obese (26% vs. 7%, respectively), and severe obesity was significantly associated with diagnos

285 To investigate the genetic architecture of severe obesity, we performed a genome-wide association s

286 n all F0-F3 patients with mild, moderate, or severe obesity were $48,836/QALY, $24,949/QALY, and $19,

287 ntributed to the metabolomic fingerprints of severe obesity were aromatic and branched-chain amino ac

288 Obesity and severe obesity were associated with stillbirth resulting

289 New cases of adult-onset severe obesity were calculated by sex, race/ethnicity, a

290 ensitive and insulin-resistant patients with severe obesity were compared indicate that the insulin-r

291 emia, and hypertension at first diagnosis of severe obesity were each independently associated with a

292 nalling increases food intake and results in severe obesity, whereas enhanced cholinergic signalling

293 Patients with severe obesity who are unable to reduce successfully wit

294 < 0.001) compared with matched patients with severe obesity who did not undergo bariatric surgery, an

295 ty in this region in women with a history of severe obesity who have successfully lost weight (ie, fo

296 In this study, patients with severe obesity who underwent SG and RYGB lost significan

297 emi-structured interviews with Veterans with severe obesity who were referred for or underwent bariat

298 tes that the prevalence of adult obesity and severe obesity will continue to increase nationwide, wit

299 Further analysis evaluated the prevalence of severe obesity within the pool of organ donation candida

300 surgery is the most effective treatment for severe obesity; yet it is unclear whether the long-term